Rapid depletion of marbofloxacin residues in rabbit after therapeutic treatment.
Although rabbit meat production represents a very small percentage of the world meat market, this percentage has been growing continuously during the last 30 years. Rabbit is considered a minor food species, and therefore no drugs are specifically registered for this animal. This situation encourages rabbit farmers to make off-label use of antibacterial drugs authorized for food-producing animal species other than rabbits. In the present study, the distribution and elimination of the fluoroquinolone antibacterial agent marbofloxacin in rabbit muscle, liver, and kidney was investigated. Marbofloxacin was chosen as a representative of a new generation of antibacterial drugs active against most gram-positive and gram-negative bacteria and mycoplasms; it is well tolerated and has short elimination times in bovine and swine species. Rabbits were treated with marbofloxacin at 2 mg kg of body weight(-1) for 5 days. Residual concentrations in liver, kidney, and muscle tissues were determined posttreatment with high-performance liquid chromatography and fluorescence detection. Marbofloxacin was rapidly distributed and eliminated from rabbit tissues. Concentrations were higher in the liver and kidney than in muscle. However, 48 h after the end of treatment, marbofloxacin concentrations dropped below the maximum residue level fixed for this antibacterial drug in cattle and pigs. Considering the efficacy of marbofloxacin for the treatment of the most common rabbit diseases, its tolerability, and its short elimination time as verified in the present study, use of this antibacterial drug could be extended to therapeutic treatment of rabbits.
Ligabue
Matteo
M
Department of Veterinary Health and Animal Pathology, University of Bologna, Ozzano Emilia, Bologna, Italy.
Lucchetti
Dario
D
Catone
Tiziana
T
Fabrizi
Laura
L
Marvasi
Luigi
L
Zaghini
Anna
A
Coni
Ettore
E
D000818:Animals; D000890:Anti-Infective Agents / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D003257:Consumer Product Safety; D004305:Dose-Response Relationship, Drug; D004350:Drug Residues / Q000032:analysis*; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics*; D024841:Fluoroquinolones / Q000493:pharmacokinetics*; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D009132:Muscles / Q000378:metabolism; D009928:Organ Specificity; D015363:Quinolones / Q000493:pharmacokinetics*; D011817:Rabbits / Q000378:metabolism*; D014018:Tissue Distribution
D000890:Anti-Infective Agents; D004791:Enzyme Inhibitors; D024841:Fluoroquinolones; D015363:Quinolones; C080260:marbofloxacin